GlassScriptPhysician profile
Saneese Stephen
NPI 1477537025
$6,032.44
in general payments reported to CMS, 2019-2025
21 companies · $768 in 2025
The $768 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,592 · 2022: $1,101 · 2023: $1,972 · 2024: $600 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.37 |
| Education | $422.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,231.26 | 2021-2025 | |
| Astellas Pharma US INC | $769.59 | 2022-2025 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $573.75 | 2021-2024 | Opdivo, Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $445.12 | 2021-2023 | Erleada, Akeega, Tecvayli |
| Amgen INC. | $441.19 | 2021-2023 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $400.07 | 2023-2025 | |
| Exelixis INC. | $381.78 | 2022-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $264.32 | 2021-2025 | Lynparza |
| Seagen INC. | $220.91 | 2023 | Adcetris, Padcev |
| Genzyme Corporation | $217.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $187.83 | 2022-2025 | Keytruda, Welireg |
| Genentech USA, INC. | $144.23 | 2023 | Polivy |
| Regeneron Healthcare Solutions, INC. | $120.19 | 2022 | |
| Daiichi Sankyo INC. | $108.34 | 2025 | Enhertu |
| Astellas Pharma Global Development | $104.13 | 2025 | Xtandi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $102.60 | 2022 | |
| Stemline Therapeutics INC. | $100.00 | 2023 | Orserdu |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Janssen Scientific Affairs, LLC | $69.53 | 2023 | Erleada |
| Eisai INC. | $32.61 | 2024 | |
| Abbvie INC. | $17.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saneese Stephen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.